As expected, despite similar sex distribution, patients with NAFLD had higher BMI, prevalence of dyslipidemia, IR, increased liver enzymes NAFLD, serum insulin (p < 0.0001), FFAs (p < 0.0001), HOMA-IR (p < 0.0001), Adipo-IR (p < 0.0001), and lower adiponectin levels (p = 0.008) compared to healthy controls with very low probability of steatosis (Table 1). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.